Citation
- Authors: Madsen AV. et al.
- Year: 2022
- Journal: Anal Chem
- Applications: in vitro / DNA / PEIpro
- Cell type: FreeStyle 293-F
Method
All antibodies were produced by transient expression in HEK293 Freestyle cells for secretion into the culture supernatant. Plasmids encoding either HC or LC were transiently cotransfected using linear polyethylenimine (PEIPro, Polyplus-transfection) according to manufacturer instructions and transfected cells were cultured for 7 days in FreeStyle 293 Expression Medium at 37 °C and 5% CO2. We used a 3:2 (HC:LC) transfection ratio for all symmetric antibodies. For asymmetric bsAbs we used a 1.5:4:1 (HC:sdAb-Fc:LC) transfection ratio optimized for the specific sdAb-Fc/IgG construct. After incubation, the supernatants were clarified (centrifugation at 1500×g for 10 min and 0.45 μm filtering) before purification using Protein A affinity chromatography connected to an ÄKTA Pure system.
Abstract
Simultaneous targeting of different antigens by bispecific antibodies (bsAbs) is permitting synergistic binding functionalities with high therapeutic potential, but is also rendering their analysis challenging. We introduce flow-induced dispersion analysis (FIDA) for the in-depth characterization of bsAbs with diverse molecular architectures and valencies under near-native conditions without potentially obstructive surface immobilization. Individual equilibrium dissociation constants are determined in solution, even in higher-order complexes with both antigens involved, hereby allowing the analysis of binding cooperativity and elucidation of a potential interference between the interactions. We further illustrate bispecific binding functionality as incremental increases in complex sizes when the bsAbs are exposed to one or two antigens. The possibility for comprehensive binding analysis with low material consumption and high matrix tolerability irrespective of molecular format and with little optimization renders FIDA a versatile tool for format selection and characterization of complex bi/multispecific protein therapeutics throughout the drug development and biomanufacturing pipeline.